CompoAtlas

YAMAMOTO RESEARCH - ACIDO LIPOICO RETARD

Food supplement declared in France, declaration No 2020-12-776, decision dated 14 December 2020

YAMAMOTO RESEARCH - ACIDO LIPOICO RETARD, from YAMAMOTO S.P.A., is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Acide lipoïque. None of the rules we check flags an issue with its declared composition.

Brand
not provided
Food business operator placing the product on the market
YAMAMOTO S.P.A.
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Sachet
Daily dose
1 sachet par jour
Intended populations
Men, Women
Not recommended (according to the manufacturer)
Breastfeeding women, Pregnant women, Taking diabetes medication
Flavourings
citrus fruits

Declaration 171875, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Other active ingredients

NamePer day
Acide lipoïquenot declared

Additives

E330, E553b, E462, E551, E407, E955, E160a, E162

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne doivent pas se substituer à une alimentation variée et équilibrée et à un mode de vie sain. Tenir hors de la portée des jeunes enfants. Déconseillé chez les personnes diabétiques, ainsi que les femmes enceintes et allaitantes. Conserver dans un endroit frais et sec. Évitez l'exposition aux sources de chaleur et à la lumière du soleil.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Acide lipoïque
    Read the warning, when it applies and the studies cited

    DL-ALPHA-LIPOIC ACID/R-ALPHA-LIPOIC ACID

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Jacob et al. 1999, Konrad et al. 1999, Packer et al. 1995).

    Sources cited by Health Canada (3)
    • Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, Rett K. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radical Biology & Medicine 1999;27(3-4):309-314. PubMed Randomised trial
    • Konrad T, Vicini P, Kusterer K, Höflich A, Assadkhani A, Böhles HJ, Sewell A, Tritschler HJ, Cobelli C, Usadel KH. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999;22(2):280-287. PubMed
    • Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radical Biology & Medicine 1995;19(2):227-250. PubMed Review article

    Applies to products providing 42 milligrams or more DL-alpha-lipoic acid or 21 milligrams or more R-alpha-lipoic acid, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience sweating, paleness, chills, headache, dizziness and/or confusion (as these may be symptoms of serious low blood sugar) (Bae et al., 2013; Gullo et al., 2014; Bresciani et al., 2011; Chang et al., 2009).

    Sources cited by Health Canada (4)
    • Bae SM, Bae MN, Kim EY, Kim IK, Seo MW, Shin JK, Cho SR, Jeong GH. Recurrent Insulin Autoimmune Syndrome Caused by α-Lipoic Acid in Type 2 Diabetes. Endocrinol Metab (Seoul). 2013;28(4):326-330. PubMed
    • Bresciani E, Bussi A, Bazzigaluppi E, Balestrieri G. Insulin autoimmune syndrome induced by α-lipoic acid in a Caucasian woman: case report. Diabetes Care. 2011 Sep;34(9):e146. doi: 10.2337/dc11-0600. DOI
    • Chang HJ, Choi HS, Park MY, Leem SM, Jang YS, Park KS, Lee JM. A case of insulin autoimmune syndrome related to alpha-lipoic acid. Korean J Med 2009;76:600-604.
    • Gullo D, Evans JL, Sortino G, Ira D. Goldfine and Vigneri R. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking a-lipoic acid. Clinical Endocrinology 2014;81: 204-209. PubMed

    Health Canada monograph dated 27 June 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “YAMAMOTO RESEARCH - ACIDO LIPOICO RETARD: composition and regulation”, https://compoatlas.com/en/supplements/products/171875-yamamoto-research-acido-lipoico-retard, updated 15 November 2026.

List recorded in 2020. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line